Abstract
Understanding the interaction between out-expressed proteins in cancer cells and their extracellular matrix (ECM) represents a key process for improving current cancer therapies and diagnoses. ECM proteins such as fibronectin, vitronectin, and laminin can be substituted by using a small synthetic peptide named RGD (R: arginine (Arg); G: glycine (Gly); D: aspartic acid (Asp)). This synthetic peptide, in its cyclic conformation, exhibits higher stability toward sterilization, heat treatment, pH-variations, and storage. Several clinical studies involving the use of cyclic (or cyclo) RGD (cRGD) for imaging, chemotherapeutic strategies of drug delivery systems are underway.
© 2016 Japan Society of Applied Physics, Optical Society of America
PDF ArticleMore Like This
Chi Zhang, Soumik Siddhanta, Chao Zheng, and Ishan Barman
JM3A.53 Cancer Imaging and Therapy (Cancer) 2016
J. M. Lee, C. Hong, S. Adhikari, H. Jeong, Y. D. Jang, J. S. Baek, I. Yoon, and D. Lee
JW2A.75 CLEO: Applications and Technology (CLEO:A&T) 2017
F. Peyskens, A. Dhakal, P. Van Dorpe, N. Le Thomas, and R. Baets
FM4N.7 CLEO: QELS_Fundamental Science (CLEO:FS) 2016